Overview

Metformin and Congenital Nephrogenic Diabetes Insipidus

Status:
Terminated
Trial end date:
2017-06-01
Target enrollment:
0
Participant gender:
Male
Summary
The purpose of this study is to determine whether metformin can increase urine concentration (osmolality) and decrease the amount of urine in patients with congenital nephrogenic diabetes insipidus (NDI).
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Emory University
Treatments:
Arginine Vasopressin
Metformin
Criteria
Inclusion Criteria:

- Males with a documented mutation in the vasopressin type 2 receptor (V2R)

- Willing to provide consent and/or assent as appropriate

- Capable of providing urine samples as dictated by the protocol

Exclusion Criteria:

- Urinary incontinence

- Subjects who have heart disease, liver disease, diabetes, cancer, or other significant
disease other than Nephrogenic Diabetes Insipidus (NDI)

- Subjects with significant renal dysfunction (defined as a calculated glomerular
filtration rate (GFR) <80 ml/min/1.73 m^2)

- Subjects with acquired NDI